What is the 13F Pro Quality Score for STAA?

13F Pro ranks STAAR SURGICAL CO (STAA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View STAA's current score at https://13fpro.ai/research/STAA (free sign-up required for the full ranking).

Which hedge funds own the most STAA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of STAA include BROADWOOD CAPITAL, BlackRock,, Yunqi Capital Ltd. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/STAA as soon as new 13F filings post.

Where does 13F Pro source STAA data?

All STAAR SURGICAL CO fundamentals and ownership data come directly from SEC EDGAR. STAAR SURGICAL CO files with the SEC under CIK 718937. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is STAA in?

STAAR SURGICAL CO (STAA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is STAA research updated on 13F Pro?

STAA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

STAAR SURGICAL CO(STAA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 718937 STAA stock profile & AI dashboard →

13F Pro Quality Score

18.0/100

Rank #2,711 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

5.8/100

Profitability

14.9/100

Balance Sheet

15.4/100

Earnings Quality

30.0/100

Free Cash Flow

14.0/100

Institutional Flow

61.2/100

Revenue Scale

28.2/100

Dilution Risk

14.1/100

STAA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for STAAR SURGICAL CO (STAA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STAA at 18.0/100 on a 32-signal composite quality model, placing it at rank #2,711 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (5.8) and free cash flow (14.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), STAAR SURGICAL CO reports quarterly revenue of $93.5M, net income of $5.2M, free cash flow of $-22.1M. Top institutional holders of STAA by reported 13-F value include BROADWOOD CAPITAL, BlackRock,, Yunqi Capital Ltd, based on the most recent SEC filings. STAA trades on the Nasdaq exchange and files with the SEC under CIK 718937. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STAA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for STAAR SURGICAL CO directly from SEC EDGAR. STAAR SURGICAL CO's 13F Pro composite quality score has ranged between 8 and 65 since 2021, currently 18.0 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about STAAR SURGICAL CO

Quirks, history, and lore behind STAA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in Southern California.
2
The Numbers
Annual revenue in the range of $300–350 million — not huge, but it commands a premium valuation because its addressable market is enormous and largely untapped.
3
The History
Founded in the 1990s, the company spent years navigating FDA approvals before becoming a niche leader in a corner of ophthalmology that most surgeons rarely touch.
4
The Secret
Its flagship products are implantable lenses placed inside the eye — not on it — making them invisible to the wearer and a genuine alternative to LASIK for certain patients.
5
The Lore
The company is a rare pure-play on implantable collamer lenses (ICLs), and it has increasingly targeted the booming China and India markets where millions of severely myopic patients are underserved.
6
The Giveaway
Its ticker is almost as twinkly as its products: this eye-implant specialist puts tiny lenses inside your eye to fix your vision — and yes, the company name has an extra A in it, just to keep you guessing.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$93.5M

Net Income

Q1 2026

$5.2M

Free Cash Flow

Q1 2026

$-22.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+0.0% YoY

$239.4MFY 2025

FY20 $163.5MFY21 $230.5MFY22 $239.4MFY25 $239.4M

Net Income

-302.8% YoY

$-80.4MFY 2025

FY20 $5.9MFY21 $27.5MFY22 $39.7MFY25 $-80.4M

Operating Income

-309.4% YoY

$-91.7MFY 2025

FY20 $6.8MFY21 $33.3MFY22 $43.8MFY25 $-91.7M

EPS (Diluted)

-302.5% YoY

$-1.62FY 2025

FY20 $0.12FY21 $0.56FY22 $0.80FY25 $-1.62

Total Assets

+7.8% YoY

$451.7MFY 2025

FY20 $257.4MFY21 $345.8MFY22 $418.8MFY25 $451.7M

Op. Cash Flow

-195.8% YoY

$-34.2MFY 2025

FY20 $21.0MFY21 $44.0MFY22 $35.7MFY25 $-34.2M

Metric	FY 2025	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$239.4M +0.0%	$239.4M +3.9%	$230.5M +41.0%	$163.5M +8.8%	$150.2M +21.2%	$124.0M
Net Income	$-80.4M -302.8%	$39.7M +44.2%	$27.5M +365.3%	$5.9M -57.9%	$14.0M +182.8%	$5.0M
Operating Income	$-91.7M -309.4%	$43.8M +31.4%	$33.3M +392.5%	$6.8M -42.9%	$11.9M +79.7%	$6.6M
EPS (Diluted)	$-1.62 -302.5%	$0.80 +42.9%	$0.56 +366.7%	$0.12 -60.0%	$0.30 +172.7%	$0.11
Total Assets	$451.7M +7.8%	$418.8M +21.1%	$345.8M +34.3%	$257.4M +24.0%	$207.5M +24.0%	$167.3M
Operating Cash Flow	$-34.2M -195.8%	$35.7M -18.8%	$44.0M +109.8%	$21.0M -18.8%	$25.8M +102.0%	$12.8M

AI Insight: STAA Financial Trends

STAAR swung to profitability in Q2 2026 but revenue remains volatile and operating cash flow turned sharply negative.

• Net income recovered to $5M in Q2 2026 from -$18M in Q1 2026, signaling improved near-term profitability.

• Revenue oscillated between $43M and $99M over eight quarters with no sustained uptrend; Q2 2026 at $94M remains below peak.

• Operating cash flow deteriorated to -$22M in Q2 2026, the worst reading in the dataset despite positive net income.

⚠ Severe Q4 2024–Q2 2025 earnings collapse (-$105M cumulative net income) suggests operational or market disruption not yet resolved.

⚠ Operating margin remains deeply negative in Q1 2026 (-40%) and only marginally positive in Q2 2026 (9%), indicating fragile profitability.

⚠ Equity declined from $428M (Q3 2024) to $344M (Q1 2026), eroding shareholder value despite recent stabilization.

AI Insight: STAA Ratio Trends

STAA swung from -39.5% operating margin in Q1 2026 to +8.5% in Q2 2026, signaling recovery after severe 2025 disruptions.

• Operating margin rebounded to 8.5% in Q2 2026 from -39.5% in Q1 2026; NPM improved to 5.6% from -31.7%.

• ROIC recovered to 9.1% in Q2 2026 versus -26.5% in Q1 2026, approaching pre-crisis Q2 2024 level of 11.6%.

• Q3 2025 posted 19.5% operating margin and 20.9% ROIC—strongest since Q2 2024—before Q1 2026 collapse.

⚠ TTM profitability deeply negative (-9.1% OpMargin, -7.5% ROIC) despite Q2 2026 recovery; prior-year losses still dominate.

⚠ Extreme volatility: OpMargin swung from -134.8% (Q1 2025) to +19.5% (Q3 2025) to -39.5% (Q1 2026). Pattern unclear.

Get alerted when STAA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for STAAR SURGICAL CO including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of STAA

BROADWOOD CAPITAL INC
$301.5M16,123,842 sh
BlackRock, Inc.
$124.7M6,666,118 sh
Yunqi Capital Ltd
$60.9M3,257,130 sh
Madison Avenue Partners, LP
$45.7M2,441,678 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$39.7M2,123,589 sh
STATE STREET CORP
$34.3M1,832,996 sh
VANGUARD CAPITAL MANAGEMENT LLC
$31.6M1,690,606 sh
Anatole Investment Management Ltd
$30.0M1,601,701 sh
MORGAN STANLEY
$28.0M1,499,356 sh
GOLDMAN SACHS GROUP INC
$20.0M1,069,939 sh

Fund	Value	Shares
BROADWOOD CAPITAL INC	$301.5M	16,123,842
BlackRock, Inc.	$124.7M	6,666,118
Yunqi Capital Ltd	$60.9M	3,257,130
Madison Avenue Partners, LP	$45.7M	2,441,678
VANGUARD PORTFOLIO MANAGEMENT LLC	$39.7M	2,123,589
STATE STREET CORP	$34.3M	1,832,996
VANGUARD CAPITAL MANAGEMENT LLC	$31.6M	1,690,606
Anatole Investment Management Ltd	$30.0M	1,601,701
MORGAN STANLEY	$28.0M	1,499,356
GOLDMAN SACHS GROUP INC	$20.0M	1,069,939

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put STAA on your watchlist

Track score changes the day STAAR SURGICAL CO files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is STAA a good stock to buy?

13F Pro's AI-powered analysis of STAAR SURGICAL CO (STAA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STAA are available on the STAA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own STAA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STAA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of STAAR SURGICAL CO's investment landscape.